DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/grlrsd/hepatocellular) has announced the addition of the "Hepatocellular Carcinoma - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
Hepatocellular Carcinoma Overview
Pipeline Products for Hepatocellular Carcinoma - Overview
Pipeline Products for Hepatocellular Carcinoma - Comparative Analysis
Hepatocellular Carcinoma - Therapeutics under Development by Companies
Hepatocellular Carcinoma - Therapeutics under Investigation by Universities/Institutes
Hepatocellular Carcinoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Hepatocellular Carcinoma - Products under Development by Companies
Hepatocellular Carcinoma - Products under Investigation by Universities/Institutes
Hepatocellular Carcinoma - Companies Involved in Therapeutics Development
Companies Mentioned - Partial List
- 4SC AG
- AB Science SA
- AbbVie Inc.
- Acceleron Pharma, Inc.
- ACROVIS Pharma AG
- Adaptimmune Limited
- Advenchen Laboratories, LLC
- Alfact Innovation
- Alnylam Pharmaceuticals, Inc.
- Amgen Inc.
- AndroScience Corporation
- Arbutus Biopharma Corporation
- ArQule, Inc.
- Array BioPharma Inc.
- Astex Pharmaceuticals, Inc.
- AstraZeneca Plc
- AVEO Pharmaceuticals, Inc.
- Bayer AG
- Bio-Cancer Treatment International Limited
- Bioneer Corporation
- Blueprint Medicines
- Boehringer Ingelheim GmbH
- Boston Biomedical, Inc.
- Bristol-Myers Squibb Company
- Caladrius Biosciences, Inc.
- Can-Fite BioPharma Ltd.
- CASI Pharmaceuticals Inc.
- CCRP Therapeutics GmbH
- Celgene Corporation
- Celldex Therapeutics, Inc.
For more information visit http://www.researchandmarkets.com/research/grlrsd/hepatocellular